Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: chiasma.com
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
4 - CHIASMA, INC (0001339469) (Issuer)
Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to
Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the fourth quar
Jefferies downgraded Chiasma from Buy to Hold
HC Wainwright resumed coverage of Chiasma with a rating of Buy and set a new price target of $12.00 from $10.00 previously
EFFECT - CHIASMA, INC (0001339469) (Filer)
15-12B - CHIASMA, INC (0001339469) (Filer)
S-8 POS - CHIASMA, INC (0001339469) (Filer)
S-8 POS - CHIASMA, INC (0001339469) (Filer)
S-8 POS - CHIASMA, INC (0001339469) (Filer)
S-8 POS - CHIASMA, INC (0001339469) (Filer)
S-8 POS - CHIASMA, INC (0001339469) (Filer)
POS AM - CHIASMA, INC (0001339469) (Filer)
8-K - CHIASMA, INC (0001339469) (Filer)
25-NSE - CHIASMA, INC (0001339469) (Subject)